Free Trial

INSPECS Group (SPEC) Competitors

INSPECS Group logo
GBX 50 +1.00 (+2.04%)
As of 11:04 AM Eastern

SPEC vs. TSTL, BVC, AKR, CNSL, ODX, CTEC, AMS, MXCT, ARIX, and CIR

Should you be buying INSPECS Group stock or one of its competitors? The main competitors of INSPECS Group include Tristel (TSTL), BATM Advanced Communications (BVC), Akers Biosciences (AKR), Cambridge Nutritional Sciences (CNSL), Omega Diagnostics Group (ODX), ConvaTec Group (CTEC), Advanced Medical Solutions Group (AMS), MaxCyte (MXCT), Arix Bioscience (ARIX), and Circassia Group (CIR). These companies are all part of the "medical" sector.

INSPECS Group vs. Its Competitors

INSPECS Group (LON:SPEC) and Tristel (LON:TSTL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Tristel has a net margin of 15.47% compared to INSPECS Group's net margin of -2.10%. Tristel's return on equity of 20.43% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-2.10% -4.00% 0.45%
Tristel 15.47%20.43%9.89%

67.8% of INSPECS Group shares are held by institutional investors. Comparatively, 50.4% of Tristel shares are held by institutional investors. 25.6% of INSPECS Group shares are held by insiders. Comparatively, 4.9% of Tristel shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Tristel has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£195.14M0.26-£4.11M-£4.04-12.38
Tristel£42.24M4.52£6.54M£13.6629.27

In the previous week, Tristel had 3 more articles in the media than INSPECS Group. MarketBeat recorded 3 mentions for Tristel and 0 mentions for INSPECS Group. INSPECS Group's average media sentiment score of 0.00 beat Tristel's score of -0.12 indicating that INSPECS Group is being referred to more favorably in the media.

Company Overall Sentiment
INSPECS Group Neutral
Tristel Neutral

INSPECS Group pays an annual dividend of GBX 1 per share and has a dividend yield of 2.0%. Tristel pays an annual dividend of GBX 13 per share and has a dividend yield of 3.3%. INSPECS Group pays out -24.8% of its earnings in the form of a dividend. Tristel pays out 95.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

INSPECS Group has a beta of 2.22, suggesting that its share price is 122% more volatile than the S&P 500. Comparatively, Tristel has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500.

Summary

Tristel beats INSPECS Group on 9 of the 15 factors compared between the two stocks.

Get INSPECS Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPEC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPEC vs. The Competition

MetricINSPECS GroupMedical Instruments & Supplies IndustryMedical SectorLON Exchange
Market Cap£50.84M£3.56B£5.49B£2.95B
Dividend Yield2.00%1.99%5.38%5.02%
P/E Ratio-12.3819.0026.20144.07
Price / Sales0.26419.68415.50226,514.81
Price / Cash1.63146.5436.4927.97
Price / Book0.502.748.055.29
Net Income-£4.11M£99.80M£3.15B£5.90B
7 Day Performance2.88%0.83%1.92%0.74%
1 Month Performance-7.41%-0.24%4.90%4.60%
1 Year Performance-5.66%124.33%35.95%80.91%

INSPECS Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPEC
INSPECS Group
N/AGBX 50
+2.0%
N/A-7.5%£50.84M£195.14M-12.381,673Gap Up
TSTL
Tristel
N/AGBX 405
+8.7%
N/A-14.0%£193.47M£42.24M29.64208News Coverage
Gap Up
BVC
BATM Advanced Communications
N/AGBX 16.45
+1.4%
N/A-5.5%£87.36M£130.32M-381.89980Positive News
AKR
Akers Biosciences
N/AN/AN/AN/A£21.64M£2.32M-0.44120
CNSL
Cambridge Nutritional Sciences
N/AGBX 3.62
+2.0%
N/AN/A£8.61M£9.77M-362.103,200High Trading Volume
ODX
Omega Diagnostics Group
N/AN/AN/AN/A£5.23M£7.55M-220.0091Gap Down
CTEC
ConvaTec Group
1.5668 of 5 stars
GBX 291.80
+1.0%
GBX 301.67
+3.4%
+20.1%£7.42B£2.71B49.1410,000News Coverage
AMS
Advanced Medical Solutions Group
2.981 of 5 stars
GBX 215.50
+4.4%
GBX 300
+39.2%
-0.9%£465.32M£132.18M41.7610Positive News
MXCT
MaxCyte
N/AGBX 147.69
-7.7%
N/A-99.3%£194.96M£57.52M-5.4180Gap Up
High Trading Volume
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap Down

Related Companies and Tools


This page (LON:SPEC) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners